Autism Spectrum Disorder Therapeutics Market Report and Forecast 2025-2034

Autism Spectrum Disorder Therapeutics Market Overview

Autism spectrum disorder (ASD) is a neurological development disability characterized by conditions such as anxiety, depression, and attention-deficit, hyperactivity, among others. This neurological and developmental disorder can begin in infancy and last throughout adulthood throughout a person’s life. It can be diagnosed based on behavioural patterns. ASD treatments are focused on reducing the factors that interfere with an individual’s orderly functioning. Some of the drugs approved by the U.S. FDA include Risperidone and Aripiprazole for treating irritability associated with ASD.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The autism spectrum disorder therapeutics market is affected by the growing number of patients and the increasing awareness regarding the disease. The rising governmental initiatives are also expected to encourage research in this area. Further, rapid technological advancements in medicine are likely to favor market growth during the forecast period. Moreover, the adoption of behavioral therapies to overcome the communication gap in such patients is poised to aid the market expansion.

Autism Spectrum Disorder Therapeutics Market Growth Drivers

Rising Number of Pipeline Drugs Expected to Propel Market Growth

The forecast period is expected to witness rising development of drugs to treat autism spectrum disorder. The presence of a growing pipeline of ASD drugs and increasing research and development in this field is expected to boost the market growth. For instance, in 2023, STALICLA, a Swiss clinical-stage biotech company announced the completion of the phase 1b trials for STP1. The trials will allow the application of the company’s precision medicine discovery platform in ASD. The increasing research and development activities associated with autism spectrum disorder are expected to result in the introduction of new and effective treatment options, which are set to elevate the market value.

Growth in Clinical Trials to Meet Rising Autism Spectrum Disorder Therapeutics Market Demand

In March 2024, a clinical-stage biopharmaceutical company based in Israel, SciSparc Ltd., announced the dosing of the first patient in the SCI-210 clinical trial, a randomized, controlled, double-blind clinical trial for pediatric patients with autism spectrum disorder. SCI-210 treatment is a combination of CannAmide™ (palmitoylethanolamide-based tablets) and cannabidiol-rich oil (CBD). The clinical trial, which will enroll 60 children, aims to assess the safety, efficacy, and tolerability of SCI-210 for the treatment of ASD in comparison to CBD monotherapy. The surge in clinical trials, supported by substantial investment from the leading pharmaceutical companies, is anticipated to significantly contribute to the market growth.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Autism Spectrum Disorder Therapeutics Market Trends

Autism Spectrum Disorder Therapeutics Market Segmentation

Autism Spectrum Disorder Therapeutics Market Share

Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth

Based on treatment, the market is segmented into antipsychotic drugs, selective serotonin reuptake inhibitors (SSRIs), stimulants, and sleep medications, among others. These medications help in treating different aspects associated with the disorder, ranging from managing core symptoms to treating comorbid conditions. The antipsychotic drugs segment covers a significant market share owing to their efficacy in managing severe behavioral issues such as aggression, irritability, and self-injurious behaviors, which are common in individuals affected by the condition.

Autism Spectrum Disorder Therapeutics Market Analysis by Region

Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is expected to hold a significant share of the market during the forecast period, supported by the increased number of autism spectrum disorder cases in the region. The market is also supported by the presence of a favorable regulatory environment. For example, the United States Food and Drug Administration (FDA) authorized the marketing of Cognoa ASD Diagnosis Aid, a device to help diagnose autism spectrum disorder (ASD) in 2021.

The region is also characterised by research and development in the field of autism spectrum disorder which is expected to propel market growth during the forecast period. For instance, the National Institute of Mental Health headquartered in the United States, supports research focused on the treatment of autism spectrum disorder and related disorders.

Leading Players in the Autism Spectrum Disorder Therapeutics Market

Other key players in the market include Curemark LLC, Bristol Myers Squibb Co., Axial Therapeutics, Q BioMed Inc., PaxMedica, Otsuka Pharmaceutical, Stalicla SA, and Zynerba Pharmaceuticals, Inc.

Key Questions Answered in the Autism Spectrum Disorder Therapeutics Market Report

• What was the autism spectrum disorder therapeutics market value in 2024?
• What is the autism spectrum disorder therapeutics market forecast outlook for 2025-2034?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on disease type?
• What is the market breakup based on treatment type?
• What is the market breakup by age group?
• What is market segmentation based on the route of administration?
• What are the major factors aiding the autism spectrum disorder therapeutics market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How does the prevalence and incidence of autism spectrum disorder affect the market landscape?
• What are the major autism spectrum disorder therapeutics market trends?
• Which disease type will dominate the market share? 
• Which treatment type is expected to have a high market value in the coming years?
• Which route of administration will experience the highest demand in the market segment?
• Which age group is projected to contribute to the highest market growth?
• Who are the key players involved in the autism spectrum disorder therapeutics market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?